RxDoctor Payments DataLook up a doctor →

Alyssa Fikes

Family · Huntsville, ALNPI 1700474624

Payments from drug & device makers

$14,944in general payments, 2019–2025

Across 914 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$816
  • QOL Medical, LLC$451
  • Regeneron Healthcare Solutions, Inc.$436
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$14,84499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,944 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$59,917
Medicare patients
433
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide79$69,664
XifaxanRifaximin14$51,726
TrulancePlecanatide29$33,407
Dexlansoprazole DrDexlansoprazole66$26,988
Esomeprazole Magnesium155$10,395
Famotidine394$6,922
Lubiprostone25$4,721
Pantoprazole Sodium290$4,140
Mesalamine13$3,752
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates52$3,206
Budesonide DrBudesonide20$2,367
Dicyclomine Hcl71$1,724
Omeprazole110$1,698
Lansoprazole51$1,313
Sucralfate36$1,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$4,163$85,13343 claims
AbbVieLinzess$4,849$69,66479 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →